<p>艾伯維（NYSE:ABBV - 獲取免費報告）在週一發佈的研究報告中，摩根大通將其目標價從 250.00 美元上調至 260.00 美元，Benzinga 報道。該公司目前對該股票給予 “增持” 評級。摩根大通的目標價意味着該股票當前價格有 20.05% 的潛在上漲空間。</p>
<ul>
<li>ABBV 股票：250 美元可能是大幅超預期第三季度財報後的新底部</li>
</ul>
<p>其他一些股票分析師也最近對該股票進行了評論。Evercore ISI 將艾伯維的目標價從 207.00 美元上調至 222.00 美元，並在 9 月 22 日的研究報告中給予該股票 “跑贏大盤” 評級。華爾街 Zen 在 10 月 25 日的研究報告中將艾伯維的評級從 “持有” 上調至 “買入”。Piper Sandler 在 10 月 10 日的報告中將艾伯維的目標價從 231.00 美元上調至 284.00 美元，並給予該公司 “增持” 評級。Erste Group Bank 在 10 月 14 日的報告中將艾伯維的評級從 “買入” 下調至 “持有”。最後，富國銀行在 9 月 12 日的研究報告中將艾伯維的目標價從 240.00 美元上調至 260.00 美元，並給予該股票 “增持” 評級。兩位投資分析師對該股票給予強烈買入評級，十六位分析師給予買入評級，九位分析師給予持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為 236.35 美元。</p>
<p><strong>查看我們關於艾伯維的最新研究報告</strong></p>
<h2>艾伯維股票表現</h2>
<ul>
<li>為什麼艾伯維和強生可能會超越輝瑞</li>
</ul>
<p>NYSE:ABBV 週一開盤價為 216.57 美元。該公司的速動比率為 0.61，流動比率為 0.74，債務股本比率為 44.14。該公司的 50 日簡單移動平均為 222.42 美元，200 日簡單移動平均為 201.15 美元。該公司的市值為 3825.9 億美元，市盈率為 103.13，市盈增長比率為 1.42，貝塔值為 0.51。艾伯維的 52 周低點為 163.81 美元，52 周高點為 244.81 美元。</p>
<p>艾伯維（NYSE:ABBV - 獲取免費報告）最近在 10 月 31 日發佈了其財報。該公司報告本季度每股收益為 1.86 美元，超出分析師一致預期的 1.77 美元，超出幅度為 0.09 美元。該公司本季度的收入為 157.8 億美元，而一致預期為 155.8 億美元。艾伯維的淨利潤率為 6.45%，股本回報率為 699.66%。與去年同期相比，該公司的收入增長了 9.1%。在去年同期，該公司每股收益為 3.00 美元。艾伯維已將其 2025 年第四季度的指導目標設定為 3.320-3.360 每股收益。整體來看，股票分析師預計艾伯維在當前財政年度的每股收益為 12.31 美元。</p>
<h2>內部人士下注</h2>
<ul>
<li>3 只卓越股票以建立長期財富</li>
</ul>
<p>在相關消息中，執行副總裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股該股票。股份以平均價格 198.42 美元出售，總交易額為 8,407,055.40 美元。出售後，該執行副總裁在公司持有 177,292 股，價值 35,178,278.64 美元。這代表其持股減少了 19.29%。該交易在與證券交易委員會的法律文件中披露，相關信息可通過此鏈接獲取。此外，執行副總裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股該公司的股票。股份以平均價格 198.51 美元出售，總價值為 2,639,190.45 美元。出售完成後，該執行副總裁在公司持有 58,247 股，價值 11,562,611.97 美元。該交易使其持股減少了 18.58%。該銷售的 SEC 文件提供了更多信息。目前，0.25% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>一些大型投資者最近調整了對該公司的持股。Conning Inc.在第二季度將其在艾伯維的持股增加了 7.1%。Conning Inc.現在擁有 191,023 股該公司的股票，價值 35,458,000 美元，此前在上個季度增持了 12,690 股。Dohj LLC 在第二季度將其在艾伯維的持股增加了 41.8%。Dohj LLC 現在擁有 4,529 股該公司的股票，價值 802,000 美元，此前在上個季度增持了 1,335 股。第一夏威夷銀行在第二季度將其在艾伯維的持股增加了 0.8%。第一夏威夷銀行現在擁有 7,556 股該公司的股票，價值 1,403,000 美元，此前增持了 60 股。Narus Financial Partners LLC 在第一季度將其在艾伯維的持股增加了 25.3%。Narus Financial Partners LLC 現在擁有 1,988 股該公司的股票，價值 417,000 美元，此前增持了 401 股。最後，BankPlus 信託部門在第二季度將其在艾伯維的持股增加了 3.3%。BankPlus 信託部門現在擁有 27,113 股該公司的股票，價值 5,033,000 美元，此前增持了 855 股。目前，70.23% 的股票由機構投資者和對沖基金持有。</p>
<h2>艾伯維公司簡介</h2>
<p>（獲取免費報告）</p>
<p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性關節炎和克羅恩病；Rinvoq 用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
<h2>推薦故事</h2>
<ul>
<li>我們更看好的五隻股票，勝過艾伯維</li>
<li>何時出售股票以獲利或止損</li>
<li>波音在 2018 年以來最佳交付季度中逼近空客</li>
<li>如何購買黃金股票並投資黃金</li>
<li>將其放在我的卡上：奢侈品牌與支付公司為何相得益彰</li>
<li>萬億美元市值的意義超越了數字</li>
<li>適合任何市場的三隻安全穩健股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
<p>在考慮艾伯維之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而艾伯維並不在名單上。</p>
<p>雖然艾伯維目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

艾伯維

<p>摩根大通已將艾伯維（NYSE:ABBV）的目標價格從 250.00 美元上調至 260.00 美元，維持 “增持” 評級。這個新目標暗示當前股價有 20.05% 的上漲潛力。其他分析師也調整了對艾伯維的評級和目標價格，平均評級為 “適度買入”，目標價格為 236.35 美元。艾伯維最近公佈了強勁的第三季度財報，超出預期，每股收益為 1.86 美元，營收為 157.8 億美元，同比增長 9.1%</p>

<p>AbbVie (NYSE:ABBV - Get Free Report) had its target price upped by JPMorgan Chase &amp; Co. from $250.00 to $260.00 in a research note issued on Monday,Benzinga reports. The firm currently has an &#34;overweight&#34; rating on the stock. JPMorgan Chase &amp; Co.'s target price points to a potential upside of 20.05% from the stock's current price.</p>
<div class="lb-trans"><p>艾伯維（NYSE:ABBV - 獲取免費報告）在週一發佈的研究報告中，摩根大通將其目標價從 250.00 美元上調至 260.00 美元，Benzinga 報道。該公司目前對該股票給予 “增持” 評級。摩根大通的目標價意味着該股票當前價格有 20.05% 的潛在上漲空間。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大幅超預期第三季度財報後的新底部</li>
</ul>
</div><p>A number of other equities analysts also recently commented on the stock. Evercore ISI boosted their target price on shares of AbbVie from $207.00 to $222.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, September 22nd. Wall Street Zen raised shares of AbbVie from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, October 25th. Piper Sandler upped their target price on shares of AbbVie from $231.00 to $284.00 and gave the company an &#34;overweight&#34; rating in a report on Friday, October 10th. Erste Group Bank cut shares of AbbVie from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, October 14th. Finally, Wells Fargo &amp; Company upped their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an &#34;overweight&#34; rating in a research report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $236.35.</p>
<div class="lb-trans"><p>其他一些股票分析師也最近對該股票進行了評論。Evercore ISI 將艾伯維的目標價從 207.00 美元上調至 222.00 美元，並在 9 月 22 日的研究報告中給予該股票 “跑贏大盤” 評級。華爾街 Zen 在 10 月 25 日的研究報告中將艾伯維的評級從 “持有” 上調至 “買入”。Piper Sandler 在 10 月 10 日的報告中將艾伯維的目標價從 231.00 美元上調至 284.00 美元，並給予該公司 “增持” 評級。Erste Group Bank 在 10 月 14 日的報告中將艾伯維的評級從 “買入” 下調至 “持有”。最後，富國銀行在 9 月 12 日的研究報告中將艾伯維的目標價從 240.00 美元上調至 260.00 美元，並給予該股票 “增持” 評級。兩位投資分析師對該股票給予強烈買入評級，十六位分析師給予買入評級，九位分析師給予持有評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為 236.35 美元。</p>
</div><p><strong>View Our Latest Research Report on AbbVie</strong></p>
<div class="lb-trans"><p><strong>查看我們關於艾伯維的最新研究報告</strong></p>
</div><h2>AbbVie Stock Performance</h2>
<div class="lb-trans"><h2>艾伯維股票表現</h2>
</div><ul>
<li>Why AbbVie and Johnson &amp; Johnson Could Outperform Pfizer</li>
</ul>
<div class="lb-trans"><ul>
<li>為什麼艾伯維和強生可能會超越輝瑞</li>
</ul>
</div><p>NYSE:ABBV opened at $216.57 on Monday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The company has a fifty day simple moving average of $222.42 and a two-hundred day simple moving average of $201.15. The company has a market cap of $382.59 billion, a price-to-earnings ratio of 103.13, a price-to-earnings-growth ratio of 1.42 and a beta of 0.51. AbbVie has a 52 week low of $163.81 and a 52 week high of $244.81.</p>
<div class="lb-trans"><p>NYSE:ABBV 週一開盤價為 216.57 美元。該公司的速動比率為 0.61，流動比率為 0.74，債務股本比率為 44.14。該公司的 50 日簡單移動平均為 222.42 美元，200 日簡單移動平均為 201.15 美元。該公司的市值為 3825.9 億美元，市盈率為 103.13，市盈增長比率為 1.42，貝塔值為 0.51。艾伯維的 52 周低點為 163.81 美元，52 周高點為 244.81 美元。</p>
</div><p>AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company's revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, equities analysts anticipate that AbbVie will post 12.31 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>艾伯維（NYSE:ABBV - 獲取免費報告）最近在 10 月 31 日發佈了其財報。該公司報告本季度每股收益為 1.86 美元，超出分析師一致預期的 1.77 美元，超出幅度為 0.09 美元。該公司本季度的收入為 157.8 億美元，而一致預期為 155.8 億美元。艾伯維的淨利潤率為 6.45%，股本回報率為 699.66%。與去年同期相比，該公司的收入增長了 9.1%。在去年同期，該公司每股收益為 3.00 美元。艾伯維已將其 2025 年第四季度的指導目標設定為 3.320-3.360 每股收益。整體來看，股票分析師預計艾伯維在當前財政年度的每股收益為 12.31 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><ul>
<li>3 Exceptional Stocks to Build Long-Term Wealth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只卓越股票以建立長期財富</li>
</ul>
</div><p>In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Also, EVP Nicholas Donoghoe sold 13,295 shares of the firm's stock in a transaction on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total value of $2,639,190.45. Following the completion of the sale, the executive vice president owned 58,247 shares in the company, valued at $11,562,611.97. The trade was a 18.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Azita Saleki-Gerhardt 在 8 月 12 日的交易中出售了 42,370 股該股票。股份以平均價格 198.42 美元出售，總交易額為 8,407,055.40 美元。出售後，該執行副總裁在公司持有 177,292 股，價值 35,178,278.64 美元。這代表其持股減少了 19.29%。該交易在與證券交易委員會的法律文件中披露，相關信息可通過此鏈接獲取。此外，執行副總裁 Nicholas Donoghoe 在 8 月 5 日的交易中出售了 13,295 股該公司的股票。股份以平均價格 198.51 美元出售，總價值為 2,639,190.45 美元。出售完成後，該執行副總裁在公司持有 58,247 股，價值 11,562,611.97 美元。該交易使其持股減少了 18.58%。該銷售的 SEC 文件提供了更多信息。目前，0.25% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently modified their holdings of the business. Conning Inc. grew its position in AbbVie by 7.1% during the 2nd quarter. Conning Inc. now owns 191,023 shares of the company's stock worth $35,458,000 after acquiring an additional 12,690 shares during the last quarter. Dohj LLC boosted its position in shares of AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company's stock valued at $802,000 after purchasing an additional 1,335 shares in the last quarter. First Hawaiian Bank raised its stake in AbbVie by 0.8% during the 2nd quarter. First Hawaiian Bank now owns 7,556 shares of the company's stock worth $1,403,000 after buying an additional 60 shares during the period. Narus Financial Partners LLC raised its stake in AbbVie by 25.3% during the 1st quarter. Narus Financial Partners LLC now owns 1,988 shares of the company's stock worth $417,000 after buying an additional 401 shares during the period. Finally, BankPlus Trust Department raised its stake in AbbVie by 3.3% during the 2nd quarter. BankPlus Trust Department now owns 27,113 shares of the company's stock worth $5,033,000 after buying an additional 855 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些大型投資者最近調整了對該公司的持股。Conning Inc.在第二季度將其在艾伯維的持股增加了 7.1%。Conning Inc.現在擁有 191,023 股該公司的股票，價值 35,458,000 美元，此前在上個季度增持了 12,690 股。Dohj LLC 在第二季度將其在艾伯維的持股增加了 41.8%。Dohj LLC 現在擁有 4,529 股該公司的股票，價值 802,000 美元，此前在上個季度增持了 1,335 股。第一夏威夷銀行在第二季度將其在艾伯維的持股增加了 0.8%。第一夏威夷銀行現在擁有 7,556 股該公司的股票，價值 1,403,000 美元，此前增持了 60 股。Narus Financial Partners LLC 在第一季度將其在艾伯維的持股增加了 25.3%。Narus Financial Partners LLC 現在擁有 1,988 股該公司的股票，價值 417,000 美元，此前增持了 401 股。最後，BankPlus 信託部門在第二季度將其在艾伯維的持股增加了 3.3%。BankPlus 信託部門現在擁有 27,113 股該公司的股票，價值 5,033,000 美元，此前增持了 855 股。目前，70.23% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>AbbVie Company Profile</h2>
<div class="lb-trans"><h2>艾伯維公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥品。該公司提供 Humira，一種用於自身免疫性和腸道貝赫切特病及膿皮病的注射劑；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性關節炎和克羅恩病；Rinvoq 用於治療類風濕性關節炎、銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節炎、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌患者；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than AbbVie</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Boeing Closes in on Airbus With Best Delivery Quarter Since 2018</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Put It on My Card: Why Luxury Brands and Payments Firms Pair Well</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>3 Safe and Steady Stocks for Any Market</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過艾伯維</li>
<li>何時出售股票以獲利或止損</li>
<li>波音在 2018 年以來最佳交付季度中逼近空客</li>
<li>如何購買黃金股票並投資黃金</li>
<li>將其放在我的卡上：奢侈品牌與支付公司為何相得益彰</li>
<li>萬億美元市值的意義超越了數字</li>
<li>適合任何市場的三隻安全穩健股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=ABBV"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in AbbVie Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在艾伯維嗎？</h2>
</div><p>Before you consider AbbVie, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮艾伯維之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而艾伯維並不在名單上。</p>
</div><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然艾伯維目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

艾伯維（NYSE:ABBV）被摩根大通給予新的 260.00 美元目標價